Articles tagged with Lung Cancer
A special issue of the Journal of the American College of Radiology highlights the transformation of lung cancer from a feared and stigmatized disease to one that is increasingly understood as chronic and treatable. Advances in screening, therapeutics, and survivorship have improved outcomes for patients.
Mayo Clinic researchers have found several previously unknown genetic and cellular processes that occur in lung adenocarcinoma tumors responding well to immunotherapy. The study identified markers that may predict a positive response to immunotherapy, including the presence of senescent tumor cells and loss of the PRKCI gene.
A population-based cohort study found that individuals following high-glycemic index diets had a 13% higher chance of developing lung cancer compared to those on low-GI diets. In contrast, those consuming high-glycemic load diets experienced a 28% lower risk of lung cancer.
A recent study led by Dr. Leah Backhus found that lung cancer patients often receive inadequate posttreatment surveillance, which can lead to a substantial gap in care. The study estimated the true surveillance rates and predictors of guideline-concordant care in patients with early-stage non-small cell lung cancer.
Current USPSTF guidelines exclude two-thirds of patients from age-based screening, disproportionately affecting women and never-smokers. Age-based screening has been shown to improve detection and demonstrated superior cost-effectiveness compared to existing programs.
Lung cancer screening has the potential to prevent 3 times more deaths and gain 3 times more life-years than current levels. Increasing awareness and accessibility of lung cancer screening could lead to wider adoption.
Researchers have shown that disabling the NRF2 gene with CRISPR technology can restore drug sensitivity and slow tumor growth in lung cancer. The approach, which targets a master switch for resistance, has potential across multiple tumor types.
Researchers at The University of Osaka have developed a novel Balloon-Assisted Bronchoscope Delivery (BDBD) technique, enabling safe access to small, early-stage lung cancers hidden in the peripheral lung fields. This innovation promises to revolutionize both early diagnosis and minimally invasive treatment.
The new clinical cancer research center will support lung and genitourinary cancers, serving as a central hub for seven VA medical centers. The grant aims to improve access to precision oncology trials and patient care for veterans diagnosed at later stages.
This pilot study evaluated the effectiveness of improved laser ablation with saline injection in treating early-stage lung adenocarcinoma. The modified system significantly expanded ablation zones, achieving a 100% complete ablation rate in six patients. The treatment was safe and effective, with no major complications reported.
Researchers found that Biaxially rotational dynamic radiation therapy (BROAD-RT) significantly reduced radiation doses to lungs, heart, and oesophagus compared to volumetric modulated arc therapy (VMAT). However, it resulted in greater low-dose lung exposure.
Researchers at Arizona State University discovered that SerpinB3 plays a natural role in the body's wound-healing process, helping skin recover after damage. The protein helps activate keratinocytes to rebuild tissue and improve skin strength.
Researchers at University of Texas M. D. Anderson Cancer Center discover that inflammation is responsible for driving the earliest stages of lung cancer, identifying potential targets for early intervention and suggesting a promising approach to intercepting lung cancer development.
Researchers discovered that blocking a specific protein called ferroptosis suppressor protein 1 (FSP1) reduces tumor growth by up to 80% in mice with lung adenocarcinoma. This study provides hope for developing novel clinical therapies for cancer patients.
A UT Dallas team developed an electrochemical biosensor that accurately identifies eight volatile organic compounds linked to thoracic cancers. AI analysis enhances the accuracy of breath samples, showing promise for early lung cancer detection and improved patient outcomes.
Scientists at Moffitt Cancer Center identify distinct approaches to combat drug resistance in non-small cell lung cancer, targeting RAS and CDK12/13 pathways. Combining therapies delays or prevents resistance, extending treatment response.
Patients with advanced lung and skin cancer who received a COVID-19 mRNA vaccine within 100 days of starting immunotherapy drugs lived significantly longer. The vaccine was associated with a near doubling of median survival, from 20.6 months to 37.3 months in lung cancer patients.
A new digital health program has been found to significantly increase lung cancer screening rates among people at high risk. The study, which tested a direct-to-patient program, showed that 24.5% of participants completed a screening CT scan within 16 weeks, compared to 17% in the usual care group.
A direct-to-patient digital health intervention increased lung cancer screening rates compared to enhanced usual care. The study's findings suggest that such interventions could improve lung cancer screening across diverse populations and healthcare settings.
UCLA investigators unveil decade-long survival data for immunotherapy in advanced lung cancer and promising results for novel therapies targeting PSMA, DKK1, and FGFR3 in various aggressive cancers. These breakthroughs hold promise for improved treatment outcomes and quality of life for patients with difficult-to-treat diseases.
A recent study found that patients with advanced lung and skin cancer who received a COVID-19 mRNA vaccine within 100 days of starting immunotherapy drugs lived significantly longer than those who did not get the vaccine. The observation marks a significant step toward a long-awaited universal cancer vaccine to boost tumor-fighting eff...
Researchers discovered craters on the surface of melanoma cells that serve as immune hubs and facilitate local tumor killing. These structures, termed CRATERs, may serve as a more accurate marker of immunotherapy's success in treating solid tumors.
The phase 3 FLAURA2 study shows that adding platinum-pemetrexed to osimertinib improves overall survival in patients with newly diagnosed EGFR-mutated advanced NSCLC. Median overall survival was 47.5 months, compared to 37.6 months with osimertinib alone.
UCSF researchers found a key cellular switch driving pulmonary fibrosis and developed a new therapy to block it in mice. The treatment works by preventing healthy lung cells from converting to harmful cell types, reducing scarring and improving lung function.
A comprehensive, multidisciplinary approach led to a nearly 72% lung cancer screening rate at the University of Rochester Medical Center. The program's success was attributed to collaboration among primary care and specialty teams, leveraging technology to flag eligible patients and streamline screenings.
Dana-Farber researchers present promising phase 3 trial results for breast, lung, and bladder cancers, including improved quality of life for metastatic breast cancer patients. The trials also explore new approaches to kidney cancer treatment and real-world data analysis for metastatic breast cancer.
A significant association was found between increased lung cancer incidence and higher reported exposure levels among World Trade Center (WTC) responders. Future studies will investigate specific exposures and histologic changes to clarify the role of WTC exposure on prognosis.
A new grading system for invasive squamous cell carcinoma of the lung has been proposed based on tumor budding, with tumors classified as low-grade (0-9 buds/0.785 mm²) or high-grade (≥10 buds/0.785 mm²). The system was validated in a test set and demonstrated improved prognostic accuracy and guide treatment decisions.
A new clinical trial report finds that stereotactic radiation therapy offers long-term survival outcomes comparable to surgery for patients with small, early-stage non-small cell lung cancer. The study included a larger patient population than previously published randomized studies and followed these patients for much longer.
Researchers found that SBRT and surgery had similar 10-year outcomes for patients with early-stage non-small cell lung cancer, with radiation offering quality-of-life benefits. The study also showed a higher acute complication rate caused by surgery.
A new robot-assisted bronchoscope has been shown to diagnose tiny lung tumors in hard-to-reach areas with over 84% success rate, more than three times higher than traditional methods. The technology enables accurate diagnosis in patients where conventional bronchoscopy offers no viable option.
Researchers at Graz University of Technology created a highly detailed digital twin of the A549 lung cancer cell line, paving the way for individualized cancer treatment. The model simulates calcium dynamics and electrical voltages, allowing for testing of drugs and personalized treatment strategies.
Armida Labs will use the funding to advance preclinical studies of Targefrin, a potential clinical candidate for pancreatic and other cancers. The grant aims to develop an anti-metastatic agent that targets the EphA2 protein, which drives cancer cell invasion and metastasis.
A new AI-powered deep learning model has been shown to accurately estimate the malignancy risk of lung nodules, achieving high detection rates while reducing false-positive results. The model outperformed existing probability-based tools in a retrospective study, with a relative reduction of 39.4% in false positives.
Researchers found that lung cancer cells can form functional synapses with neurons, supporting their growth and survival. Disrupting glutamate signalling led to lower tumour burden and longer survival in experimental mice, highlighting promising therapeutic targets.
A new study at WCLC demonstrates that monitoring circulating tumor DNA can refine and personalize the use of consolidation immunotherapy in patients with limited-stage small cell lung cancer. Early ctDNA detection after induction chemotherapy identifies patients more likely to benefit from consolidation immunotherapy.
Emphysema detected on low-dose chest CT scans in asymptomatic adults increases mortality risk over a 25-year follow-up period. The study found that emphysema severity is associated with higher COPD and cardiovascular disease mortality rates, suggesting it as a distinct disease entity linked to poorer health outcomes.
A large-scale survey by Lung Cancer Europe identified critical communication barriers affecting information access and understanding among lung cancer patients and caregivers. The study found that complex medical language was a major obstacle to shared decision-making, with only 56% of respondents feeling their opinion was considered i...
The PALOMA-2 study found that subcutaneous amivantamab every 4 weeks, combined with daily oral lazertinib, yields a high objective response rate in patients with previously untreated EGFR-mutated advanced non-small cell lung cancer. This dosing regimen offers fewer administration-related reactions and improved convenience for patients.
A randomized Phase II trial shows that resecting the primary thoracic tumor after EGFR TKI therapy may prolong disease control in patients with metastatic EGFR-mutated non-small cell lung cancer. The study aims to extend the benefits of EGFR TKI beyond standard monotherapy by targeting residual disease through surgery.
A phase 2a clinical trial investigated an experimental viral immunotherapy, CAN-2409, in patients with unresectable stage III/IV NSCLC who previously failed to respond adequately to ICI. Patients showed longer overall survival and increased cytotoxic effector T cells after treatment.
A clinical trial found that patients with mesothelioma who received combination immunotherapy drugs before surgery had successful surgeries and improved early outcomes. The study showed that tracking tumor DNA in the blood could help predict treatment benefit.
A new study suggests that low-dose CT screening may be effective for detecting lung cancer in Asian women who have never smoked. The Female Asian Nonsmoker Screening Study found a lung cancer detection rate of 1.3% among the screened population.
A UK study found that lung cancer screening can benefit older adults up to age 80 who are eligible for surgery. The research, presented at the International Association for the Study of Lung Cancer World Conference on Lung Cancer, showed comparable survival rates between younger and older patients treated with surgery.
A phase III trial found hypofractionated radiotherapy (HypoRT) with concurrent chemotherapy provides similar survival outcomes and reduced toxicity compared to the standard six-week conventional fractionated radiotherapy (ConvRT) schedule for patients with limited-stage small cell lung cancer (LS-SCLC). Patients receiving HypoRT experi...
The DeLLphi-303 trial demonstrates tarlatamab's safety and efficacy as a first-line maintenance treatment for ES-SCLC, with median OS of 25.3 months and PFS of 5.6 months. The combination also showed a manageable safety profile, with cytokine release syndrome being the most common adverse event.
A meta-analysis of randomized trials comparing video-assisted thoracoscopic surgery (VATS) and open lobectomy found a 21% reduced risk of death in VATS patients. The study also showed no difference in disease-free survival between the two groups.
The Phase 1CA240-0007 trial demonstrates a 29% overall response rate and 80% disease control rate for BMS-986504 in heavily pretreated patients with MTAP-deleted NSCLC. The agent selectively targets the PRMT5-MTA complex while sparing normal tissue.
Concurrent durvalumab therapy did not improve overall survival compared to consolidation alone in unresectable stage 3 NSCLC patients. The trial enrolled 662 patients and showed median OS was 41.5 months in the concurrent arm versus 39.4 months in the consolidation arm.
The NADIM ADJUVANT Phase III trial suggests that adding nivolumab to adjuvant chemotherapy can reduce recurrence risk and may offer meaningful clinical benefit for patients with completely resected stage IB–IIIA non-small cell lung cancer. The three-year relapse rate was 26.7% in the experimental arm versus 40.1% in the control arm.
A Phase 1 study of SHR-4849 demonstrated early signs of anti-tumor activity in patients with relapsed small cell lung cancer, with an objective response rate of 59.5% and disease control rate of 90.5%. The drug showed manageable safety and favorable pharmacokinetics.
Zidesamtinib demonstrated clinically meaningful activity and durability in patients with ROS1-positive NSCLC who had progressed on prior TKI therapy. Durable responses were observed in patients with CNS involvement, ROS1 G2032R mutations, and multiple prior ROS1 TKIs.
The ACROSS 2 Phase III trial demonstrates that combining aumolertinib with platinum-pemetrexed chemotherapy significantly improves progression-free survival in patients with advanced/metastatic NSCLC harboring EGFR sensitizing mutations and concomitant tumor suppressor gene mutations. The treatment regimen showed a manageable safety pr...
The FLAURA2 trial shows osimertinib plus chemotherapy significantly improves overall survival compared to osimertinib monotherapy in patients with EGFR-mutated advanced NSCLC. The combination also demonstrates a manageable safety profile, extending survival for these patients.
The Phase 2 IDeate-Lung01 trial demonstrated a confirmed objective response rate of 48.2% and disease control rate of 87.6% in patients with recurrent or progressive ES-SCLC. Ifinatamab deruxtecan showed manageable safety and high response rates, supporting further investigation in small cell lung cancer.
A Phase 3 trial found that crizotinib did not prolong disease-free survival in patients with resected early-stage ALK+ NSCLC. The study included 166 patients and followed them for a median of 58.3 months.
The global Phase 3 HARMONi trial found that ivonescimab plus chemotherapy significantly prolonged progression-free survival (PFS) in patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR mutations. Median PFS was 6.8 months, and the overall response rate was higher in the ivonescimab group.
A novel antibody-drug conjugate iza-bren demonstrated an objective response rate of 66.0% and a confirmed ORR of 56.0% in EGFR-mutated NSCLC patients, with manageable safety profile. The median progression-free survival was 12.5 months.
The CheckMate 77T trial confirms that perioperative nivolumab does not compromise health-related quality of life in patients with resectable non-small cell lung cancer, including those with Stage III N2 disease. Nivolumab also reduces risk of symptom deterioration in these high-risk patients.
A combination of iza-bren and osimertinib demonstrated a 100% objective response rate in patients with first-line EGFR-mutated locally advanced or metastatic non-small cell lung cancer. The regimen was also manageable from a safety perspective, with most treatment-related adverse events being hematologic.